Dynavax Technologies Corporation (DVAX) analyst actions
Rating and price-target actions on DVAX in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the DVAX overview →
2 measured DVAX analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial | Press release | +0.20% | +0.30% | |
| Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program | Press release | +0.09% | -1.84% |
Keep exploring
More DVAX: earnings → · SEC filings → · DVAX overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| XOMA Royalty Corporation (XOMA) | 313 | 0.00% | 48% |
| Gen Digital Inc. (GEN) | 312 | +0.08% | 52% |
| National HealthCare Corporation (NHC) | 310 | 0.00% | 49% |
| NeuroOne Medical Technologies Corporation (NMTC) | 310 | -0.19% | 41% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.